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Available online 19 February 2008Benzodiazepine (BZ) site ligands affect vigilance, anxiety, memory processes, muscle tone
and epileptogenic propensity throughmodulation of neurotransmission at GABAA receptors
containing α1, α2, α3 or α5 subunits, and may have numerous experimental and clinical
applications. The ability of non-selective BZ site inverse agonists to enhance cognition,
documented in animalmodels andhuman studies, is clinically not feasible due to potentially
unacceptable psychomotor effects. Most investigations to date have proposed the α1 and/or
α5 subunit-containing GABAA receptors as comprising the memory-modulating population
of these receptors. The novel ligand PWZ-029, which we synthesized and characterized
electrophysiologically, possesses in vitro binding selectivity and moderate inverse agonist
functional selectivity at α5-containing GABAA receptors. This ligand has also been examined
in rats in the passive and active avoidance, spontaneous locomotor activity, elevated plus
maze and grip strength tests, primarily predictive of the effects on the memory acquisition,
basal locomotor activity, anxiety level and muscle tone, respectively. The improvement of
task learningwas detected at the dose of 5mg/kg in the passive, but not active avoidance test.
The inverse agonist PWZ-029 had no effect on anxiety or muscle tone, whereas at higher
doses (10 and 20 mg/kg) it decreased locomotor activity. This effect was antagonized by
flumazenil and also by the lower (but not the higher) dose of an agonist (SH-053-R-CH3-2′F)
selective for GABAA receptors containing the α5 subunit. The hypolocomotor effect of PWZ-
029 was not antagonized by the antagonist ß-CCt exhibiting a preferential affinity for α1-
subunit-containing receptors. These data suggest that moderate negative modulation at
GABAA receptors containing the α5 subunit is a sufficient condition for eliciting enhancedKeywords:
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151B R A I N R E S E A R C H 1 2 0 8 ( 2 0 0 8 ) 1 5 0 – 1 5 9encoding/consolidation of declarative memory, while the influence of higher doses of
modulators at these receptors onmotor activity shows an intricate pattern whose relevance
and mechanism await to be defined.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Themajority of fast inhibitory neurotransmission in themam-
malian central nervous system is mediated by GABAA recep-
tors. They are, as awhole, profoundly involved in the regulation
of vigilance, anxiety, memory processes, muscle tone and
epileptogenic propensity (Rudolph and Möhler, 2004). Beside
the multiplicity of subunits comprising the GABAA receptor
pentamer (19 subunits have been identified to the present;
Simon et al., 2004), the variety of possibilities for fine tuning of
neurotransmission stems from a number of allosteric mod-
ulatory sites. It is well established that ligands of the benzo-
diazepine (BZ) binding site may exert their effects through
modulation of four distinct populations of GABAA receptors,
containing theα1,α2,α3 orα5 subunit in addition to theγ2 anda
β subunit (Sieghart and Sperk, 2002; Rudolph andMöhler, 2004).
The recent genetic studies withmice carrying a pointmutation
of histidine to arginine in α1, α2, α3 or α5 subunits, rendering
the respectiveGABAA receptors selectively insensitive to effects
ofBZsite ligands, suggesteda specific contributionof individual
receptor subtypes to the spectrum of behavioral actions of
these compounds (Rudolph and Möhler, 2004). These genetic
advances have encouraged synthesis of new, selective BZ site
ligands, that possess affinity and/or efficacy profiles which
enable separation of wanted from unwanted effects (Sieghart
and Ernst, 2005).
One desirable property in this regard is the pro-mnesic
activity of BZ site inverse agonists, repeatedly reported in
animal models (e.g. Venault et al., 1986; Jensen et al., 1987), as
well as in humanvolunteers (e.g. Dorow et al., 1983; Duka et al.,
1996). However, this desirable effect is confounded by different
concomitant psychomotor effects (increased vigilance, anxio-
genic and/or proconvulsant state), some of which have been
described in memory studies with non-selective inverse
agonists in humans, urging their early termination (Dorow
et al., 1983). Point mutated mice could not be used to identify
the receptor subtypes mediating the pro-mnesic activity of
inverse agonists because an unexplained switch to the agonist
mode of action occurs when an inverse agonist at wild type
diazepam-sensitive recombinant GABAA receptors is tested at
the respective point-mutated receptors (Benson et al., 1998;
Crestani et al., 2002a). Thus, inverse agonists exertedagonistic-
like sedative and anticonvulsant effects inmicewith thepoint-
mutated α1 subunits (Crestani et al., 2002a), while correspond-
ing experiments in models of learning and memory were not
performed. Nevertheless, behavioral examination of geneti-
cally modified animals conducted to date has indicated the α1
and α5 subunit-containing GABAA receptors comprise the
‘memory-modulating’ population of these receptors (Rudolph
et al., 1999; Collinson et al., 2002; Crestani et al., 2002b). It is
notable that GABAA receptors containing the α5 subunit are
abundantly expressed in the hippocampus (Pirker et al., 2000;
Sieghart and Sperk, 2002), the structure substantially involvedin memory formation (Izquierdo and Medina, 1997). Recent
evidence from animal studies with affinity-selective (Atack
et al., 2006a) or efficacy-selective ligands (Chambers et al.,
2003; Dawson et al., 2006, Collinson et al., 2006) has confirmed
that the α5 subunit was significantly involved in cognition
enhancement mediated by the negative modulation of GABAA
receptor functions. Moreover, it was shown in humans that
pre-treatment with an α5 efficacy-selective inverse agonist
significantly reduces the amnesic effect of alcohol on learning
a word list (Nutt et al., 2007). However, the affinity- or efficacy-
selectivity of the ligands, as well as the diversity of the behav-
ioral tasks used in their characterization to date,was of limited
extent, which necessitates screening of newer BZ site negative
ligands, to determine the putative therapeutic role of such
compounds in various disorders with diminished cognitive
capabilities in humans (Maubach, 2003).
In this regard, the BZ site ligand PWZ-029 was synthesized
(Fig. 1a). Its efficacy profile was examined by two-electrode
voltage clamp experiments in Xenopus oocytes expressing re-
combinant GABAA receptor subtypes. The behavioral effects
on adult male Wistar rats were evaluated in the passive and
active avoidance, spontaneous locomotor activity, elevated
plus maze and grip strength tests, primarily predictive of de-
tecting the changes in the memory acquisition, basal locomo-
tor activity, anxiety level and muscle tone, respectively.2. Results
2.1. Electrophysiological experiments
In vitro data for PWZ-029 (Fig. 1b) demonstrated that at con-
centrationsup to 1 μMthis ligand engendered a significant partial
inverse agonist efficacy at the α5-containing GABAA receptors
(reduction of control current by 20%), whereas its activity at the
other three types of receptors tended tobeweakly and forα1- and
α3-containing receptors significantlyagonistic. Similarly, at 10μM
concentrations PWZ-029 exhibited a weak but significant partial
agonistic effect at α1- and α3-containing receptors. The lower
potencies of PWZ-029 for α1-, α2- and α3-, relative to the α5-
containingGABAAreceptors,deduced fromtherespectiveefficacy
curves, conform with the explicit binding affinity data (Table 1).
Hence, PWZ-029 shows a distinct affinity-, potency-, as well as
efficacy-selectivity for the α5-containing GABAA receptors. PWZ-
029 exerted negligible activity in 42 other receptor and enzyme
assays (B. Rothetal.,NIMHPsychoactiveDrugScreeningProgram,
UNC, unpublished results, available at https://kidbdev.med.unc.
edu/pdsp). The invitroconcentration–effects curves forSH-053-R-
CH3-2′F, the ligand used for interaction study in the locomotor
activity test, showed that it is a high-efficacy agonist at the α5-
containingGABAA receptors,withvery lowefficacies atα1,α2and
α3-containing subtypes (Rowlett, Furtmüller, Cook, unpublished
Fig. 2 – The effects of DMCM (0.2 mg/kg) and PWZ-029
(2, 5 and 10 mg/kg) on retention performance in a passive
avoidance task (*p<0.05 compared to solvent (SOL) group).
Number of animals per treatment: 10.Fig. 1 – Concentration–effects curve for modulation of GABA
elicited currents by PWZ-029 (a) on Xenopus oocytes
expressing GABAA receptor subtypes α1β3γ2, α2β3γ2,
α3β3γ2, andα5β3γ2 (b). Concentrations of GABA that elicit 3%
of the maximum GABA-triggered current of the respective
cells were applied alone and with various concentrations of
PWZ-029. Control currents represent responses in the
absence of PWZ-029.Data points representmeans±SEM from
4 oocytes from ≥2 batches. 1 µMPWZ-029 resulted in 114±4%,
105±8%, 118±5% and 80±4% of control current (at GABA EC3)
in α1β3γ2, α2β3γ2, α3β3γ2, and α5β3γ2 receptors,
respectively. All these values except the one for α2β3γ2
receptors were significantly different from that of the
respective control currents ( p<0.01, Student's t-test).
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congener SH-053-R-CH3 (Savić et al., 2008), except for greater
potencies and α5-efficacy of SH-053-R-CH3-2′F.
2.2. Passive avoidance
The acquisition session latencies did not differ significantly
irrespective of the treatment administered 15 min before theTable 1 – Binding affinity (Ki, nM) at human recombinant
GABAA receptors containingβ3, γ2 and namedα subunit,
stably expressed in mouse fibroblast L(tk−) cells a
α1 α2 α3 α4 α5 α6
N300 N300 N300 ND 38.8 N300
920b 30.0b
a Affinity wasmeasured using [3H]flumazenil (for α1-, α2-, α3-, and α5-
containing recombinant receptors), and [3H]Ro 15-4513 (for α6-
containing recombinant receptors) as radioligands, according to the
method described in Huang et al., 1996. ND — not determined.
b Recent binding affinity, based on the radioligand binding assay
described in Lameh et al., 2001, obtained using the transiently
transfected Sf9 insect cell line; data by DeLorey et al.,
unpublished results.session (data not shown). The influence of the pre-acquisition
treatment on the retention trial latency was significant [H(4)=
11.45, p=0.022] (Fig. 2). Subsequent Dunn's test indicated that
DMCM (0.2 mg/kg) and PWZ-029 at 5 mg/kg, administered
before the acquisition session, significantly increased reten-
tion session latency relative to the control group.
2.3. Active avoidance
Fig. 3a shows that DMCM (0.1 mg/kg) and PWZ-029 (2–10 mg/
kg) did not affect acquisition of avoidance responses on the
training day [F(4, 35)=0.19, p=0.98]. Retention AA performance
on the second day was significantly altered by the treatment
before the acquisition session [F(4, 35)=2.82, p=0.039]; how-
ever, the DMCM (0.1 mg/kg), but not the PWZ-029, was
effective (Dunnett's test) (Fig. 3b). Neither of the motor
parameters measured (habituation crossings, intertrial cross-
ings) differed significantly on the training or testing day (data
not shown).
2.4. Locomotor activity assay
2.4.1. Whole chamber-activity
An ANOVA showed a significant effect of treatment on total
distance travelled during 30 min of monitoring (F(4,43)=4.06,
p=0.007) (Fig. 4, whole bars). According to Dunnett's test, the
two higher doses of PWZ-029 (10 and 20 mg/kg) exerted the
activity-decreasing effect related to solvent.When the ANOVA
with post hoc analysis was applied on the 5-min intervals of
travelled distance (Fig. 5), it turned out that locomotor activity
was significantly depressed in the time periods 0–10 min
(DMCM 2mg/kg and PWZ-029 10 and 20mg/kg), 10–15min and
20–25 (PWZ-029 20 mg/kg). It is notable that in the periods 15–
20 min, 20–25 min and 25–30 min the rats treated with DMCM
(2 mg/kg) travelled on average for 23%, 21% and 96% greater
distance, respectively, than control animals; the difference did
not reach statistical significance at either of the periods
(Student's t-test).
Fig. 5 – The effects of DMCM (2 mg/kg) and PWZ-020 (5, 10
and 20 mg/kg) on the distance travelled in 5-min intervals in
the activity assay. *p<0.05 compared to solvent (SOL) group.
Number of animals per treatment was 10, except for
PWZ-029 (8 rats).
Fig. 4 – The effects of DMCM (2 mg/kg) and PWZ-020 (5, 10
and 20 mg/kg) on distance travelled in the central (hatched
bars) and peripheral (open bars) zone of the activity chamber
during 30 min of recording (total activity corresponds to the
height of the whole bar). *p<0.05 compared to solvent (SOL)
group. Number of animals per treatment was 10, except for
PWZ-029 (8 rats).
Fig. 3 – The effects of DMCM (0.2 mg/kg) and PWZ-029
(2, 5 and 10 mg/kg) on acquisition (a) and retention
(b) performance in an active avoidance task (*p<0.05
compared to solvent (SOL) group). Number of animals per
treatment: 8.
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AnANOVA showed a significant effect of treatment on distance
travelled in the arbitrarily set central parts of the chamber
during 30 min of monitoring (F(4,43)=4.35, p=0.005) (Fig. 4,
hatched bars); the effects of PWZ-029 10 and 20 mg/kg wereFig. 6 – The influence of addition of antagonists
(flumazenil — FLU and ß-CCt — bCCt) and the agonist
SH-053-R-CH3-2′F (SH-2′F-R) on the effect of PWZ-029,
administered with solvent (SOL+PWZ-029), on distance
travelled in the central (hatched bars) and peripheral (open
bars) zone of the activity chamber during 30 min of recording
(total activity corresponds to the height of the whole bar).
*p<0.05 compared to solvent (SOL+SOL) group. +p<0.05
compared to SOL+PWZ-029 group, Student's t-test. Number
of animals per treatment, for SOL+SOL through
SH-053-R-CH3-2′F, respectively, was: 7, 7, 7, 6, 7, 8, 8, and 8.
Fig. 7 – The effects of DMCM (1.25 mg/kg) and PWZ-029
(5,10 and 20mg/kg) on the a) distance travelled on open arms,
b) percentage of entries in open arms and c) percentage of
time spent on open arms of the EPM. Number of animals per
treatment group was 8. *p<0.05 compared to solvent (SOL)
group.
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treatment on activity in peripheral parts of the chamber (Fig. 4,
open bars)was similar: F(4,43)=2.91, p=0.033; PWZ-029 20mg/kg
significantly decreased activity (Dunnett's test).
2.4.3. Antagonism of the effect of PWZ-029
Both ß-CCt (30mg/kg) and flumazenil (10mg/kg), the α1-affinity-
selective and non-selective antagonist of BZ site, respectively,
failed to affect on their own the total distance travelled in thewhole chamber, whereas only flumazenil reversed the suppres-
sion of locomotion induced by PWZ-029. The α5-selective agonist
SH-053-R-CH3-2′F showsadose-dependenthypolocomotor influ-
enceonrats in thespontaneous locomotoractivityassay,with the
effective dose of 30 mg/kg (Savić, Furtmüller, Cook, unpublished
data).WhencombinedwithPWZ-02920mg/kg, thedoseof10mg/
kg, but not 20 mg/kg, of SH-053-R-CH3-2′F antagonized the effect
of the inverse agonist. There were no significant differences
among groups in distances travelled in the central zone of the
activity chamber (Fig. 6).
2.5. Elevated plus maze
2.5.1. Activity-related parameters
The influence of treatment on closed arm entries (F(4,35)=
0.23, p=0.922), total arm entries (F(4,35)=1.54, p=0.213) and
total distance travelled (F(4,35)=1.44, p=0.241) did not reach
statistical significance.
2.5.2. Anxiety-related parameters
The overall influence of treatment on distance travelled in
open arms (Fig. 7a) was not significant (F(4,35)=2.04, p=0.11).
There were significant effects of treatment on the percentage
of open arm entries (F(4,35)=4.21, p=0.007) (Fig. 7b) and
percentage of time spent on open arms (F(4,35) =3.13,
p=0.026) (Fig. 7c). In both cases, the effective treatment was
DMCM 1.25 mg/kg.
2.6. Grip strength test
According to ANOVA, the overall influence of treatment on
grip strength was not significant (F(4,35)=2.31, p=0.077). The
grip strength (mean±SEM) of rats treated with solvent, DMCM
1.25mg/kg, PWZ-029 5mg/kg, PWZ-029 10mg/kg and PWZ-029
20 mg/kg was 505.0±11.4 g, 561.1±29.3 g, 546.5±42.7 g, 468.0±
23.3 g, and 467.2±27.1 g, respectively.3. Discussion
The present results demonstrated that PWZ-029, a novel BZ site
ligand, possesses in vitro binding selectivity as well as moderate
inverseagonist functional selectivity for theα5-containingGABAA
receptors, which has translated into the pro-mnesic effect
detected in the PA, but not AA, learning task in rats. It has been
shown that the non-selective inverse agonist DMCM enhances
retention performancewhen administered at a small dose before
the acquisition session of the active (Savić et al., 2005a), or passive
(File andPellow, 1988; Savić et al., 2005b) avoidance test, and these
findingswere replicated as apositive control in thepresent study.
The interactions between DMCM and the antagonists flumazenil
and ß-CCt have suggested that the α1-subunit is substantially
involved in processing of both of these memory tasks, whereas
the interactionsbetweenagonists (midazolamandzolpidem)and
antagonistspointed to the importanceof someotherα-subunit(s),
in addition to the α1-subunit, in the passive, but not active
avoidance task (Savić et al., 2005a,b). The latter agrees well with
the memory-enhancing effect of the α5-selective inverse agonist
PWZ-029, a ligand supposedly largely inactive at α1-containing
GABAA receptors, in the PA task only.
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important characteristics, including the type of memory
assessed and the brain regions involved in memory proces-
sing. Namely, the one-trial step-through PA test assesses
declarative memory (to the point that terms such as ‘declara-
tive’ or ‘explicit’ can be applied to rodent experiments)
(Izquierdo et al., 1999), and for the retention of the task
requires the preserved hippocampus (Izquierdo and Medina,
1997). On the other hand, the two-wayAA test is an implicit, i.e.
procedural (Squire, 1992), hippocampal-independent (Gray
and McNaughton, 1983; Collinson et al., 2002) memory task.
However, as aversively motivated tests, both ‘measure’
memory of emotionally arousing experiences, and critically
involve activity of the amygdala, especially the basolateral
amygdala (McGaugh, 2004) in which the α1 subunit is themost
abundant of the six α subunits (Pirker et al., 2000; Fujimura
et al., 2005). It is felt that this fact at least in part explains the
uniform involvement of the α1 subunit-containing GABAA
receptors in modulation of memory acquisition, found for the
present (Rudolph et al., 1999; Savić et al., 2005a,b) as well as
similar, aversively motivated, memory tasks, such as the
water-lick suppression test (Rudolph et al., 1999).
Receptors containing the α5 subunit constitute a modest
fraction of BZ-sensitive GABAA receptors (approximately 5%), but
are substantially expressed in several brain regions,most notably
the hippocampus, the olfactory bulb and layers V and VI of the
neocortex (Pirker et al., 2000; Sieghart and Sperk, 2002). Studies
with untreated mice with the point mutation at the α5 subunit,
which unexpectedly displayed a partial loss, restricted to the
hippocampus, of the expression of this subunit, have indicated
the significance of the α5 subunit for learning of certain
aversively- as well as appetitively-motivated memory tasks
which require temporal integration (Crestani et al., 2002b; Yee et
al., 2004). On the other hand, in line with the present findings,
mice with the deleted α5 subunit did not differ in comparison to
the wild type controls in acquisition of the two-way AA task
(Collinson et al., 2002). The results with PWZ-029 in the present
memory tests suggest that moderate negative modulation of
GABA-ergic transmissionmediated by GABAA receptors contain-
ing the α5 subunit is a sufficient, but possibly not prerequisite
condition for eliciting enhanced encoding/consolidation of
declarative memory assessed by the PA test.
PWZ-029 had no effect on anxiety-related parameters in the
EPM, in agreement with results with the other α5-selective
inverse agonist tested in thismodel (Dawson et al., 2006); the α5
affinity-selective inverse agonist L-655,708 exerted an unusual
U-shaped anxiogenic effect in themurine EPM, butwith the use
of a non-standard statistical analysis (Navarro et al., 2002). The
effect of PWZ-029 on muscle tension measured by the grip
strength test also was absent. Hence, its hypolocomotor effect
seen in the locomotor activity assay couldnot be ascribed to any
muscle relaxation. Further, there was no hint of convulsive
activity in any of the rats treated with PWZ-029 throughout the
behavioral studies. Decreases of locomotor activity may also
reflect an increase in emotional reactivity, i.e. anxiety (cf. Atack
et al., 2005). However, such an activity was not seen with PWZ-
029 in the EPM test, nor was its hypolocomotor effect
disproportionately more pronounced in the central, more
exposed, and hence ‘emotional’, zone of the chamber, but was
notably different from standard patterns of activity of a non-selective inverse agonist (i.e. DMCM). Namely, as a rule, when
rodents explore a novel environment under the influence of a
negative modulator of GABAA receptors, locomotor activity is
depressed, but usually in a relatively short period of habituation
(e.g. Jaskiw et al., 2003); afterwards, a type of rebound
hyperlocomotion may ensue (Savić et al., 2006). However, as
we have concluded from the experiment with DMCM and the
α1-subunit-selective antagonist ß-CCt, hyperlocomotion in
habituated animals may depend primarily on the negative
modulation at α1 subunit-containing GABAA receptors (Savić et
al., 2006), and this was not observed with PWZ-029. Instead, the
temporal pattern of the extended motor depression with PWZ-
029 (20 mg/kg) wasmore similar to activity of an agonist, rather
than an inverse agonist, and the most parsimonious explana-
tion would be that, at the higher doses, PWZ-029 binds to
enough α1-containing GABAA receptors to manifest its slight
partial agonistic activity. Nevertheless, the effect of PWZ-029
was mediated by BZ site(s) (antagonism of the effect by
flumazenil) other than those at the α1-containing GABAA
receptors (lack of antagonism by ß-CCt). Comparative analysis
of invitro affinity andefficacy data of flumazenil andß-CCt (Cox
et al., 1995; June et al., 2003; Furtmüller and Sieghart, unpub-
lisheddata) suggests that theprincipal differencebetween them
lies in activity at α5 subunit-containing GABAA receptors.
Namely, flumazenil and ß-CCt show qualitatively similar
mixed antagonist/agonist efficacy profiles, with the main
distinction being at α5 subunit-containing GABAA receptors at
which ß-CCt is a weak inverse agonist, and flumazenil an
antagonist/weak agonist. Moreover, a 150-fold lower affinity of
ß-CCt for the α5 over the α1 subtype of GABAA receptors (Cox et
al., 1995) should plausibly preclude its in vivo binding at α5
subunit-containing GABAA receptors and influencing any effect
mediated by them. Hence, it is hardly conceivable that ß-CCt
may antagonize the effects of PWZ-029 at these receptors.
Similarly, the slight positive modulation at α2 or α3 subunit-
containing GABAA receptors, also observed at high doses of
PWZ-029, could hardly have contributed to its hypolocomotor
activity (cf. Low et al., 2000; Atack et al., 2006b).
Standard tests of locomotor activity were not usually
employed in reported studies with α5 subunit-selective
ligands (Atack et al., 2006a; Chambers et al., 2003; Collinson
et al., 2006; Dawson et al., 2006). Based on the results with
three novel BZ site agonists functionally silent at the α1
subunit, we recently set out the hypothesis that positive
modulation at the GABAA receptors containing α5 subunits
may contribute to sedative properties of BZ site agonists (Savić
et al., 2008). The finding that SH-053-R-CH3-2′F at the lower
(10 mg/kg), but not higher dose (20 mg/kg), antagonized the
hypolocomotor effect of PWZ-029 adds to the notion that there
may exist certain discontinuous ‘effective windows’ of the
modulation of locomotion exerted by neurons expressing the
α5-subunit-containing GABAA receptors. Namely, the max-
imal level of receptor inhibition obtainedwith PWZ (80% of the
basal GABA effects sustained by the α5-subunit-containing
receptors) is clearly different from that present inmice lacking
this subunit at all (0% of the basal GABA effects at the affected
receptors; Collinson et al., 2002) or in mice harboring a point
mutation at the α5 subunits (approximately 70% of the basal
GABA effects in the hippocampus related to the α5-subunit-
containing receptors; Crestani et al., 2002b; Hauser et al., 2005).
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with higher doses of PWZ-029, no changes in knockout mice,
stimulation/no changes inmicewithapointmutationat theα5
subunits) were apparently random in relation to the level of
receptor modulation, but certainly dependent on the stress
level and experimental settings (cf. an increase of spontaneous
locomotor activity in the mice with point-mutated α5 GABAA
receptor subunits in Hauser et al., 2005, vs. lack of changes in
Crestani et al., 2002a,b). The present hypothesis of the protean
influences of the α5-subunit-containing receptors on locomo-
tion, possibly related to the intricacy of the different processes
which are concomitantly modulated by these receptors (such
as sensorimotor gating; Hauser et al., 2005, and firing of the
layer V pyramidal neurons of the neocortex; Yamada et al.,
2007), should be checked through various locomotor tests
employing a range of doses of different α5 subunit-selective
ligands, both as single treatments and in combination.
In conclusion, examination of the present results suggests
that the negative modulation engendered by the novel BZ site
ligand PWZ-029, which demonstrates binding and functional
selectivity for the α5-containing GABAA receptors, may be
sufficient to effect enhanced formation of declarative mem-
ory. The sedative-like effects, seen at doses higher than those
affecting memory formation, reduce the probability of gen-
eration of anxiogenic or proconvulsant states. The molecular
and neuronal substrates in regard to the role of α5-subunit-
containing GABAA receptors in control of vigilance, including
the proposed phenomenon of the ‘on/off switch’, may be
numerous and await to be further elucidated.4. Experimental procedures
4.1. Drugs
PWZ-029 (methyl(8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-
imidazo[1,5-α][1,4]benzodiazepin-3-yl)methyl ether), SH-053-
R-CH3-2′F (the (R) stereoisomer of 8-ethynyl-6-(2-fluorophe-
nyl)-4-methyl-4H-2,5,10b-triaza-benzo[e]azulene-3-carboxylic
acid ethyl ester) and the preferential α1-subunit-selective
antagonist ß-carboline-3-carboxylate-t-butyl ester (ß-CCt)
were synthesized at the Department of Chemistry and
Biochemistry, University of Wisconsin — Milwaukee. The
non-selective antagonist flumazenil was donated from F.
Hoffman-La Roche (Basel, Switzerland) and the non-selective
inverse agonist DMCM was purchased from Research Bio-
chemicals Incorporated (Natick, MA, USA).
4.2. Electrophysiological experiments
Cloning of GABAA receptor subunits α1, β3 and γ2 into pCDM8
expression vectors (Invitrogen, CA) has been described else-
where (Fuchs et al., 1995). cDNAs for subunits α2, α3 and α5
were gifts from P. Malherbe and were subcloned into pCI-
vector. After linearizing the cDNA vectors with appropriate
restriction endonucleases, capped transcripts were produced
using the mMessage mMachine T7 transcription kit (Ambion,
TX). The capped transcripts were polyadenylated using yeast
poly(A) polymerase (USB, OH) and were diluted and stored in
diethylpyrocarbonate-treated water at −70 °C.The methods used for isolating, culturing, injecting and
defolliculating of the oocytes were identical as described pre-
viously (Sigel, 1987; Sigel et al., 1990). Briefly, mature female
Xenopus laevis (Nasco, WI) were anaesthetized in a bath of
ice-cold 0.17% Tricain (Ethyl-m-aminobenzoat, Sigma, MO)
before decapitation and removal of the frog's ovary. Stages 5 to
6 oocytes with the follicle cell layer around them were singled
out of the ovary using a platinum wire loop. Oocytes were
stored and incubated at 18 °C inmodified Barths' Medium (MB,
containing 88 mM NaCl, 10 mM HEPES–NaOH (pH 7.4), 2.4 mM
NaHCO3, 1 mM KCl, 0.82 mM MgSO4, 0.41 mM CaCl2, 0.34 mM
Ca(NO3)2) that was supplemented with 100 U/ml penicillin and
100 µg/ml streptomycin. Oocytes with follicle cell layers still
around them were injected with a total of 2.25 ng of cRNA.
cRNA ratio used was 1:1:5 for the α subunits, β3 and γ2,
respectively. After injection of cRNA, oocytes were incubated
for at least 36 hours before the enveloping follicle cell layers
were removed. To this end, oocytes were incubated for 20 min
at 37 °C in MB that contained 1 mg/ml collagenase type IA and
0.1mg/ml trypsin inhibitor I-S (both Sigma). This was followed
by osmotic shrinkage of the oocytes in doubly concentrated
MB medium supplied with 4 mM Na-EGTA and manually
removing of the follicle cell layer. After peeling off the follicle
cell layer, the cells were allowed to recover overnight before
being used in electrophysiological experiments.
For electrophysiological recordings, oocytes were placed on
a nylon-grid in a bath of Xenopus Ringer solution (XR, contain-
ing90mMNaCl, 5mMHEPES–NaOH (pH7.4), 1mMMgCl2, 1mM
KCl and 1mMCaCl2). The oocyteswere constantlywashed by a
flow of 6 ml/min XR which could be switched to XR containing
GABA and/or drugs. Drugs were diluted into XR from DMSO-
solutions resulting in a final concentration of 0.1% DMSO
perfusing theoocytes. Drugswerepreapplied for 30 s before the
addition of GABA, which was coapplied with the drugs until a
peak response was observed. Between two applications,
oocytes were washed in XR for up to 15 min to ensure full
recovery from desensitization. For current measurements the
oocytes were impaled with two microelectrodes (2–3 mΩ)
which were filled with 2 mM KCl. All recordings were per-
formed at room temperature at a holding potential of −60 mV
using aWarner OC-725C two-electrode voltage clamp (Warner
Instruments, Hamden, CT). Data were digitised, recorded and
measured using a Digidata 1322A data acquisition system
(Axon Instruments, Union City, CA). Results of concentration
response experiments were graphed using GraphPad Prism
4.00 (GraphPad Software, San Diego, CA). Datawere graphed as
mean±SEM of at least four oocytes from at least two batches.
4.3. Behavioral experiments
Experimentswere carried out onmaleWistar rats (Military Farm,
Belgrade, Serbia), weighing 220–250 g. All procedures in the study
conformed to EEC Directive 86/609 and were approved by the
Ethical Committee on Animal Experimentation of the Medical
Faculty in Belgrade. The rats were housed in transparent plastic
cages, six animals per cage, and had free access to pelleted food
and tapwater. The temperature of the animal roomwas 22±1 °C,
the relativehumidity40–70%, the illumination120 lux, and the12/
12 h light/dark period (light on at 6:00 h). All handling and testing
tookplace during the light phase of the diurnal cycle. Throughout
157B R A I N R E S E A R C H 1 2 0 8 ( 2 0 0 8 ) 1 5 0 – 1 5 9the study the animalswere used only once, with exception of the
grip strength measurement, which was done immediately after
the tracking of behavior on the elevated plusmaze. Spontaneous
locomotor activity and elevated plus maze behavior were
analyzed by the ANY-maze Video Tracking System software
(Stoelting Co., Wood Dale, IL, USA). All drugs were dissolved/
suspendedwith the aid of sonication in a solvent containing 85%
distilledwater, 14% propylene glycol, and 1%Tween 80, andwere
administered intraperitoneally in a volume of 1 ml/kg, 15 min
before behavioral testing (for active and passive avoidance test,
before the acquisition session). Time of administration, aswell as
the doses of DMCM in various tests were chosen based on our
previousstudies (Savićetal., 2005a,b; 2006). For interactionstudies
in the locomotor activity assay, the first treatment indicated in
combinationwasadministered into the lower left quadrant of the
peritoneum 20 min before testing, and the second treatment
5 min later into the lower right quadrant of the peritoneum.
4.4. Passive avoidance (PA) paradigm
The experiments were performed in an adapted Automatic
reflex conditioner (Ugo Basile, Milan, Italy, Model 7051), as
described earlier (Savić et al., 2005b). In short, the apparatus
consisted of a shuttle-box, equipped with a grid floor and
divided with a sliding door into a lit and a dark compartment,
and a programming unit. The animals were submitted to two,
24-h-separated sessions. The acquisition session started by
placing individual subjects in the illuminated compartment.
After 30 s, the entrance to the dark compartment was opened,
and as soon as the rat had entered it with all four paws, the
footshock (2 s, 0.3mA) was delivered. Immediately afterwards,
the rat was returned to its home cage. The same procedure
was repeated 24 h later (retention session), without footshock.
A cut-off time of 180 s was used on the training day, whereas,
on the retention trial, a ceiling of 300 s was imposed.
4.5. Two-way active avoidance (AA) paradigm
The AA test was performed in automated two-way shuttle-
boxes (Campden Instruments, Sileby, UK), as described earlier
(Savić et al., 2005a). In short, the animals were submitted to
two, 24-h-separated sessions. Training and test sessions were
procedurally identical. Animals were placed singly into the
shuttle-box and left to freely explore for 15 min, and ha-
bituation crossings were automatically counted. Afterward,
they received 30 tone foot shock trials. During the first 5 s of
each trial, a sound signal was presented (broadband noise of
69 dB), allowing the animal to avoid shocks by moving to the
other compartment (avoidance response). If the animal did
not respond within this period, a foot shock of 0.5 mA (7-s
duration) was applied. Crossing to the adjacent compartment
during the shock discontinued its delivery. The animal could
move freely in the apparatus between trials (18-s intertrial
intervals), and the intertrial crossings were automatically
counted.
4.6. Measurement of locomotor activity
Activity of single rats in a clear Plexiglas chamber
(40×25×35 cm) under dim red light (20 lux) was recorded for
a total of 30 min, without any habituation period, using ANY-maze software (as described above). For purposes of improving
data analysis, the central 20% of the chamber (200 cm2) was
virtually set as a central zone. The minimum percentage of
animal that must have been in the zone for an entry to occur
was set at 70%, and 50% of the animal must have remained in
the zone for an exit not to occur.
4.7. Behavior on the elevated plus maze (EPM)
The apparatus consisted of two open (50×10 cm, with a ledge
of 0.3 cm) and two enclosed arms (50×10×40 cm), connected
by a junction area (10×10 cm). The illumination in the
experimental room was 10 lux on the surface of the arms. At
the beginning of the experiment, single rats were placed in the
center of the maze, facing one of the enclosed arms, and their
behavior was recorded for 5 min. An entry into an open or
closed arm was scored when 90% of the animal crossed the
virtual line separating the central square of themaze from the
arm, whereas an exit occurred when more than 90% of the
animal left the respective arm. After each trial, the maze was
cleaned with dry and wet towels.
4.8. Grip strength test
Muscle strength was assessed by the grip strength meter (Ugo
Basile, Milan, Italy, model 47105). When pulled by the tail, the
rat grasps the trapeze connected to a force transducer, and the
apparatusmeasures the peak force of experimenter's pull (in g)
necessary to overcome the strength of the animal's forelimbs
grip. Each animal was given three consecutive trials, and the
median value was used for further statistics.
4.9. Statistical analysis
All numerical data presented in the figures were given as the
mean±SEM, except for results from PA test (median latency
with 25th, 75th interquartile range; data were non-parametric
because the procedure involved a cut-off). For electrophysio-
logical data Student's t-test was used for statistical analysis.
Data from PA test were assessed by a Kruskal–Wallis non-
parametric ANOVA, with post hoc comparison relative to
solvent control by a Dunn's test (α=0.05). Data from the AA,
EPM, grip strength and activity assay were assessed by a one-
way ANOVA. If the ANOVA was significant, each treatment
condition was compared with control by a Dunnett's test
(α=0.05). Where appropriate, the assessment of the antagonist
influence on the inverse agonist effect was conducted by a
Student's t-test. Statistical analyses were performed with
ANY-maze Video Tracking System software (Stoelting Co.,
Wood Dale, IL, USA) and SigmaStat 2.0 (SPSS, Inc., Chicago, IL,
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